CYTO — Altamira Therapeutics Income Statement
0.000.00%
- $2.49m
- $1.91m
Annual income statement for Altamira Therapeutics, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7.26 | 5.28 | 6.87 | 18 | 5.92 |
Operating Profit | -7.26 | -5.28 | -6.87 | -18 | -5.92 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.83 | -8.22 | -6.81 | -18.7 | -7.27 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.63 | -8.2 | -6.69 | -18.7 | -7.27 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -6.63 | -8.2 | -17.1 | -26.5 | -3.87 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.63 | -8.2 | -17.1 | -26.5 | -3.87 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -912 | -545 | -172 | -233 | -14.8 |